openPR Logo
Press release

Antisense Oligonucleotides Market Report 2017 – 2027: By Application

11-30-2017 10:47 AM CET | Health & Medicine

Press release from: Future Market Insights

Antisense Oligonucleotides Market Report 2017 – 2027:

Antisense oligonucleotides (ASOs) are 15–25 nt oligonucleotides designed to tie complementary RNA targets for the degradation. They are synthesized so that they can be used to block disease processes by altering the synthesis of a specific protein. ASOs offers promising treatment options for a range of medical disorders. They facilitate the development of therapeutics affecting protein targets which cannot be treated with protein therapeutics. They can target a particular malfunctioning gene, interfere with RNA function at cellular level, and can also be silenced or modulated. It allows modifications in immune system that facilitates treatment of a wide range of autoimmune disorders – that cannot be treated with available drugs. It is easy to scale up the commercial scale GMP production of these oligonucleotides compared to other biologic therapies. Moreover, the side effects of antisense oligonucleotides are minimal and can be controlled with ease as compared to other class of drugs.

Read Report Overview @ https://www.futuremarketinsights.com/reports/antisense-oligonucleotides-market

Though, the antisense oligonucleotides market has witnessed four FDA approvals [fomivirsen (Vitravene) approved in 1998 – which was discontinued due to low demand; pegaptanib (Macugen) in 2004; mipomersen (Kynamro) in 2013; and eteplirsen (Exondys 51) in 2016). However, this market is yet to achieve recognition as a valuable drug category like biologics, small molecules, and gene and cell therapy. However, in December 2016, this was projected to change with the approval of nusinersen (Spinraza) for treating spinal muscular atrophy (SMA), which is one of the most common genetic cause for infant mortality with no approved treatments. Spinraza has shown unprecedented results for the treatment of SMA in clinical trials.

Strong pipeline of antisense oligonucleotides and increased focused on large number of product approvals and commercialization are some of the primary factors driving the growth of the global antisense oligonucleotides market. Moreover, significant advances in the field of antisense oligonucleotides at a therapeutic or clinical level is further contributing to the growth of the global antisense oligonucleotides market. However, the global antisense oligonucleotides market is grappling with numerous challenges related to diversity of oligonucleotides, delivery, and regulatory complexity. Despite several advancements at clinical levels, the delivering of active oligonucleotide to the actual site within target cells is still one of the major challenges hindering the growth of the global antisense oligonucleotides market. In addition to this, developing a new set of unique regulatory guidelines is another challenge limiting the growth of the global antisense oligonucleotides market.

Although the development of oligonucleotide therapeutics commenced in 1970s, FDA has approved only four oligonucleotide drugs (of which fomivirsen was discontinued) nearly a half century later. However, the filed is gaining momentum and is set to offer promising growth opportunities with a strong pipeline of 135 oligonucleotides in various stages of clinical trials. Even when the market performance of antisense oligonucleotides is not predictable as like other segments of the industry, the future looks very promising primarily reflected by the leadings players in the market and the amount of research and development investments.

Geographically, the global antisense oligonucleotides market is segmented into regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, Japan, Middle East and Africa. North America clearly dominates the global antisense oligonucleotides market due to a strong product pipeline and increasing number of FDA approvals in the region.

Request Sample Report @ https://www.futuremarketinsights.com/reports/sample/rep-gb-5377

Some of the players identified in the global antisense oligonucleotides market include Ionis Pharmaceuticals, Inc., Sarepta Therapeutics, Biogen, Alnylam Pharmaceuticals, Inc., Antisense Therapeutics Limited, Isarna Therapeutics GmbH, Arrowhead Pharmaceuticals, Inc., Atlantic Pharmaceuticals, Inc., Enzon Pharmaceuticals, Inc., Bio-Path Holdings, Inc., Gene Signal International SA, GlaxoSmithKline plc, Geron Corporation, Gradalis, ICO Therapeutics, Aptose Biosciences, Marina Biotech, miRagen Therapeutics, Inc., Synlogic, Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd, Regulus Therapeutics Inc., Rexahn Pharmaceuticals, Inc., and RXi Pharmaceuticals, among others.

ABOUT US:

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

ABOUT US:

Future Market Insights (FMI) is a leading market intelligence and consulting firm. We deliver syndicated research reports, custom research reports and consulting services, which are personalized in nature. FMI delivers a complete packaged solution, which combines current market intelligence, statistical anecdotes, technology inputs, valuable growth insights, an aerial view of the competitive framework, and future market trends.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Antisense Oligonucleotides Market Report 2017 – 2027: By Application here

News-ID: 839196 • Views:

More Releases from Future Market Insights

Electronic Tongue Market will grow USD 774.2 million by 2035, at a 4.5% CAGR, fueled by demand for smart diagnostics and medical R&D.
Electronic Tongue Market will grow USD 774.2 million by 2035, at a 4.5% CAGR, fu …
The global electronic tongue market is advancing rapidly, poised to reach USD 497.9 million in 2025 and climb to USD 774.2 million by 2035, growing at a promising 4.5% CAGR. The increasing demand for precision diagnostics, pharmaceutical quality control, and personalized medicine is driving this technological surge, positioning the electronic tongue as a futuristic, non-invasive diagnostic instrument in healthcare and pharmaceuticals. Electronic tongues, by design, mimic human sensory functions through an
ESD Tapes and Labels market will expand USD 4,253.3 million by 2035, growing at 4.5% CAGR with strong electronics and aerospace demand.
ESD Tapes and Labels market will expand USD 4,253.3 million by 2035, growing at …
The global market for ESD (electrostatic discharge) tapes and labels is entering a new decade of expansion driven by technological innovation, the rise of miniaturized electronics, and heightened quality standards in manufacturing. Valued at USD 2,738.8 million in 2025, the market is expected to reach USD 4,253.3 million by 2035, expanding at a steady 4.5% CAGR. This reflects a world increasingly dependent on efficient anti-static solutions that ensure the protection
Catalase Market will rise USD 575.9 million by 2035 at 3.1% CAGR, driven by sustainable innovations and expanding applications.
Catalase Market will rise USD 575.9 million by 2035 at 3.1% CAGR, driven by sust …
The global market for catalase is preparing for steady long-term expansion, driven by green chemistry, renewable sourcing, and biotechnology-driven production upgrades. Projected to reach USD 424.5 million in 2025 and USD 575.9 million by 2035, the industry's 3.1% CAGR reflects its broadening influence across critical sectors including food and beverages, pharmaceuticals, textiles, and personal care. With growing concerns about sustainability, efficiency, and safety, catalase is emerging as a vital biocatalyst
Quillaia Extract market is set to reach USD 1,826.9M by 2035 at 5.8% CAGR fueled by natural, functional, and sustainable trends.
Quillaia Extract market is set to reach USD 1,826.9M by 2035 at 5.8% CAGR fueled …
The global Quillaia extract market is entering a period of unprecedented growth, reflecting the world's shift toward natural, functional, and nutrient-rich ingredients. Projected to increase from USD 1,039.6 million in 2025 to USD 1,826.9 million by 2035 at a robust 5.8% CAGR, the industry's future is shaped by consumer demand for healthier, eco-friendly products and manufacturers' determination to stay ahead through innovation, expansion, and diversification. Over the past few years, Quillaia

All 5 Releases


More Releases for Pharmaceuticals

Cystic fibrosis Market: Epidemiology, Therapies, Companies, DelveInsight | Veron …
Cystic fibrosis therapies, such as TRIKAFTA, SYMDEKO, KALYDECO, VX-121/TEZ/ VX-561, Ensifentrine, and others, are expected to boost the Cystic fibrosis Market in the upcoming years. DelveInsight has launched a new report on "Cystic fibrosis - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Cystic fibrosis, historical and forecasted epidemiology as well as the Cystic fibrosis market trends in the United States, EU5 (Germany, Spain, Italy, France,
Gastritis Drugs Market Size Report 2032 | Regeneron Pharmaceuticals, Sanofi, Han …
DelveInsight's "Gastritis Market Insights, Epidemiology, and Market Forecast -2032" report delivers an in-depth understanding of the Gastritis, historical and forecasted epidemiology as well as the Gastritis market trends in the United States, EU4 (Germany, Spain, Italy, France) and the United Kingdom, and Japan. Key Takeaways from the Gastritis Market Research Report • The increase in Gastritis Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging
Generic Pharmaceuticals Market Set for More Growth| Hikma Pharmaceuticals, Emcur …
Advance Market Analytics published a new research publication on "Generic Pharmaceuticals Market Insights, to 2028" with 232 pages and enriched with self-explained Tables and charts in presentable format. In the Study you will find new evolving Trends, Drivers, Restraints, Opportunities generated by targeting market associated stakeholders. The growth of the Generic Pharmaceuticals market was mainly driven by the increasing R&D spending across the world. Get Free Exclusive PDF Sample Copy of
Global Halal Pharmaceuticals Market 2019 - CCM Pharmaceuticals, Pharmaniaga, Ros …
This new report by Eon Market Research, titled “Global Halal Pharmaceuticals Market 2019 Research Report, 2015 – 2025” offers a comprehensive analysis of Halal Pharmaceuticals industry at a global as well as regional and country level. Key facts analyzed in this report include the Halal Pharmaceuticals market size by players, regions, product types and end industries, history data 2014-2018 and forecast data 2019-2025. This report primarily focuses on the study
Topical Antibiotic Pharmaceuticals Market 2016-2026 | Teva Pharmaceuticals, Perr …
Topical antibiotics are applied to a certain area of the skin to kill infections. Application of topical antibiotics has a number of advantages upon comparison of systemic delivery in the treatment of skin infections. Skin and soft tissue infections (SSTIs) involve microbial invasion of the skin and underlying soft tissues infections are one of the most commonly occurring conditions amongst people. Most of these infections are minor and chronic in
Lipid Disorder Treatment Market to 2017 - 2026: Teva Pharmaceuticals, Mylan Phar …
Researchmoz added Most up-to-date research on "Lipid Disorder Treatment Market - Global Industry Analysis, Share, Size, Growth, Trends and Forecast 2017 - 2026" to its huge collection of research reports Extensive research report on global lipid disorders treatment market skilfully crafted by Transparency Market Research depicts the current as well as future scenario of various drugs used to treat lipid disorders. The research study includes analysis on key developments that are